GlassScriptPhysician profile
Charmaine Luvis
NPI 1134385776
$8,933.66
in general payments reported to CMS, 2019-2025
44 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $1,097 · 2021: $2,043 · 2022: $1,637 · 2023: $1,034 · 2024: $1,091 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,323.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,496.48 | 2021-2025 | |
| Lilly USA, LLC | $1,138.20 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $882.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $589.78 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $527.89 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $471.99 | 2019-2023 | Trintellix |
| Amgen INC. | $412.27 | 2019-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $299.77 | 2020-2024 | Nexletol |
| Pfizer INC. | $255.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $245.55 | 2019-2023 | Verquvo, Belsomra |
| Astellas Pharma US INC | $241.61 | 2019-2024 | Veozah |
| Glaxosmithkline, LLC. | $204.08 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Alkermes, INC. | $174.41 | 2022-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.11 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $157.93 | 2019-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charmaine Luvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.